Inter‐ and intraobserver variability in the evaluation of dynamic breast cancer MRI

To quantify variations within and between observers ascribable to manual region of interest (ROI) placement in patients with breast cancer undergoing dynamic MRI.

[1]  John Suckling,et al.  Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[2]  Martin A Lodge,et al.  Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ying Lu,et al.  MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer , 2001, Annals of Surgical Oncology.

[4]  L. Turnbull,et al.  Dynamic contrast‐enhanced MRI in the differentiation of breast tumors: User‐defined versus semi‐automated region‐of‐interest analysis , 1999, Journal of magnetic resonance imaging : JMRI.

[5]  D. Collins,et al.  Dynamic magnetic resonance imaging of tumor perfusion , 2004, IEEE Engineering in Medicine and Biology Magazine.

[6]  A. Padhani,et al.  Non‐invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer , 2001, The British journal of surgery.

[7]  D. Altman,et al.  Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.

[8]  A. Padhani.  Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.

[9]  A R Padhani,et al.  Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics , 1997, Journal of magnetic resonance imaging : JMRI.

[10]  David J Collins,et al.  Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. , 2004, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.

[11]  M O Leach,et al.  Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Padhani.  MRI for assessing antivascular cancer treatments. , 2003, The British journal of radiology.

[13]  J R Griffiths,et al.  Clinical studies. , 2005, Advances in pharmacology.

[14]  A R Padhani,et al.  MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.

[15]  J R Griffiths,et al.  Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. , 2003, The British journal of radiology.

[16]  A. Padhani,et al.  Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.

[17]  A. Jackson,et al.  Analysis of dynamic contrast enhanced MRI. , 2004, The British journal of radiology.

[18]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[19]  M. Knopp,et al.  Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imaging , 2003, Journal of magnetic resonance imaging : JMRI.

[20]  G Brix,et al.  Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. , 2001, Cancer research.

[21]  P. Tofts.  Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.